0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$208.00
This product is available by prescription only
This product does not require a prescription
Out Of Stock
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
The 40mg vial provides high peptide availability for multi-site or multi-arm study designs, reducing vial requirements across extended protocols and simplifying laboratory procurement. Lyophilized powder maintains stability over multi-year research programs, supporting consistent peptide exposure and reproducible experimental conditions throughout the observation period.
Tirzepatide is a synthetic peptide designed to co-activate both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors — two distinct incretin system G-protein-coupled receptors involved in pancreatic beta-cell signaling, insulin secretion pathway activity, and glucagon suppression dynamics. Dual receptor agonism enables researchers to examine whether simultaneous activation of both incretin receptor systems produces additive or synergistic effects on downstream cAMP signaling, beta-cell pathway marker expression, and glucose-dependent insulin secretion assay endpoints relative to single-receptor agonist comparators.
Produced by Elivena in USA GMP-certified facilities to approximately 99% purity, verified by independent third-party COA documentation, each 40mg vial confirms peptide sequence identity, purity grade, and batch-specific quality control data. This level of characterization provides professional laboratories with consistent, pharmaceutical-grade dual-agonist material suitable for regulatory-documentation-quality research records.
Tirzepatide supports in-vitro investigation of simultaneous GIP and GLP-1 receptor binding kinetics, receptor occupancy dynamics, and downstream cAMP second messenger pathway activity in pancreatic cell line and primary culture models. Researchers characterizing dual-agonist receptor selectivity, binding affinity profiles, and intracellular signaling cascade interactions use Tirzepatide as a primary reference compound for incretin receptor pharmacology study designs.
Laboratories studying incretin system signaling pathways use Tirzepatide to quantify downstream molecular marker expression, including insulin secretion assay endpoints, glucagon suppression pathway activity, and glucose transporter regulatory marker changes in controlled preclinical metabolic models. Multi-arm study designs comparing single-receptor and dual-receptor agonist effects on these endpoints support mechanistic characterization of incretin pathway interaction dynamics.
The 40mg concentration supports complex, multi-arm, multi-site experimental designs spanning 72 weeks or more, enabling comprehensive longitudinal characterization of dual-receptor signaling pathway activity and metabolic endpoint marker progression. Professional laboratories managing multiple concurrent dual-agonist protocols benefit from the reduced procurement frequency this concentration provides, supporting consistent material availability across long-duration study phases.
Reconstitute lyophilized Tirzepatide 40mg with sterile bacteriostatic water using GMP-compliant sterile laboratory technique. Reconstitution volume should be determined based on the target working concentration specified by the study design and institutional laboratory standards. Use calibrated laboratory equipment for all preparation steps, and document stock solution preparation in accordance with research record-keeping requirements.
Store lyophilized peptide at 2–8°C in a dark, temperature-controlled laboratory environment prior to reconstitution. Following reconstitution, maintain strict refrigeration at 2–8°C to preserve peptide stability and dual-agonist activity. Cold-chain shipping is not required, but immediate storage at 2–8°C upon receipt is recommended to ensure optimal peptide integrity throughout the protocol period. Each Elivena vial is supplied with COA documentation and handling guidance.
Professional research programs may extend 104 weeks or more for complete dual-agonist receptor characterization. Studies systematically monitor metabolic signaling panels, receptor pathway activity markers, and molecular endpoint expression at defined intervals. The 40mg concentration supports efficient long-term study execution with consistent, reliable peptide availability across all protocol phases.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic dual-peptide formulation combining amylin analog and GLP-1 receptor agonist for dual-mechanism pathway studies and combination peptide research in controlled laboratory environments.
Research-grade synthetic peptide inhibitor designed for experimental peptide-protein interaction research in controlled laboratory settings.
Research-grade cathelicidin-derived peptide formulated for experimental immune-related research in controlled laboratory environments.
Research-grade synthetic dual-agonist peptide formulated in higher-quantity 15mg format for extended dual-receptor pathway studies and institutional peptide research in controlled laboratory environments.
